Korea develops oral bacteria-based vaccine mechanism vs Covid-19

Lee Byung-moon and Minu Kim 2022. 1. 7. 14:21
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Research of oral Covid-19 vaccine based on gut-microbiome science
Korea University’s Allergy Immunology Center on Thursday said its research team has successfully developed an oral bacteria-based vaccine technology which can be safely used as a platform for an orally-administered vaccine as an alternative to current intramuscular jabs against coronavirus strains and new infectious diseases in the future.

For the vaccine, a well-known salmonella strain was used as a vaccine delivery candidate. Recombinant salmonella cells expressing engineered viral proteins related with Covid-19 pathogenesis were engineered, and the formulation of the oral vaccine candidate strain was evaluated in mice. The vaccine promoted antigen-specific antibody production, and cellular and humoral immunity was induced with no significant toxicity effects, according to the research.

Graphical abstract to show the mechanism of orally-administered Covid-19 vaccine
The platform technology studied jointly with Dr. Bang Iel-soo, a professor of Department of Microbiology and Immunology, Chosun University School of Dentistry, was developed by Yoon Won-suck, a professor of Allergy Immunology Center, Korea University, as part of establishing a preemptive measure in response to the emergence of harmful microorganisms in the future by examining the distribution of microorganisms in multi-use facilities across the country.

This study is significant in that it has developed a microbial fusion technology for various harmful microorganisms that may appear after the coronavirus pandemic, Dr. Yoon said, hoping that the technology will be utilized as a next-generation vaccine platform applicable to various diseases in the future.

The research findings were published in VACCINES on January 1, 2022 under the title of ‘Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2'. The technology was also filed for patent protection in Korea.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?